MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Inclusion Criteria: The following criteria must be fulfilled for the provision of Managed Access and will vary depending on the stage of the product lifecycle: * An independent request should be received from the Treating Physician (in some instances from Health Authorities, Institutions or Governments); * The patient to be treated has a serious or life threatening disease or condition, and no comparable or satisfactory alternative therapy is available to monitor or treat the disease or condition; * The patient is not eligible or able to enroll in a clinical trial; * There is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated; * Provision of the investigational product will not interfere with the initiation, conduct or completion of a Novartis clinical trial or overall development program and * Such access provision as described above is allowed as per local laws and regulations. Exclusion Criteria: Patients eligible for inclusion in this Treatment Plan have to meet all of the following criteria: 1. Male or Female patients age ≥ 18 years 2. WHO Performance Status of 0, 1 or 2 3. Relapsed or refractory Ph+ ALL 4. Imatinib (or dasatinib) must be discontinued at least 5 days prior to beginning therapy 5. Normal organ, electrolyte and marrow functions as described below: * Absolute Neutrophil Count (ANC) ≥ 1.0 x 1000000000/L * Platelets 50 x 1000000000/L * Potassium ≥ LLN (Lower limit of normal) or corrected to within normal limits with supplements prior to the first dose of nilotinib * Total calcium (corrected for serum albumin) ≥ LLN * Magnesium ≥ LLN or corrected to within normal limits with supplements prior to the first dose of nilotinib medication * AST and ALT ≤ 2.5 x ULN or ≤ 5.0 x UL:N if considered due to tumor * Alkaline phosphatase ≤ 2.5 x ULN * Serum bilirubin ≤ 1.5 x ULN * Serum amylase and lipase ≤ 1.5 x ULN